Streetbeat News

Price Targets

IVZ

Goldman Sachs analyst Alexander Blostein has maintained a Neutral rating on Invesco (NYSE:IVZ) and reduced the price target from $18.25 to $18.

Portfolio Pulse from Benzinga Newsdesk

January 12, 2024 | 2:24 pm

HP

Goldman Sachs analyst Neil Mehta has maintained a Sell rating on Helmerich & Payne (NYSE:HP) and reduced the price target from $37 to $33.

Portfolio Pulse from Benzinga Newsdesk

January 12, 2024 | 2:22 pm

NTR

Raymond James analyst Steve Hansen has downgraded Nutrien (NYSE:NTR) from Outperform to Market Perform and reduced the price target from $80 to $65.

Portfolio Pulse from Benzinga Newsdesk

January 12, 2024 | 2:17 pm

KOF

UBS analyst Rodrigo Alcantara has upgraded Coca-Cola Femsa SAB de (NYSE:KOF) from Neutral to Buy and increased the price target from $83 to $109, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

January 12, 2024 | 2:06 pm

CHK

Citigroup analyst Paul Diamond has upgraded Chesapeake Energy (NASDAQ:CHK) from Neutral to Buy and increased the price target from $82 to $95, indicating a positive outlook for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

January 12, 2024 | 2:02 pm

PEAK

Scotiabank analyst Nicholas Yulico has upgraded Healthpeak Properties (NYSE:PEAK) from Sector Perform to Sector Outperform and set a price target of $23.

Portfolio Pulse from Benzinga Newsdesk

January 12, 2024 | 2:00 pm

JAMF

Analyst ratings for Jamf Holding (NASDAQ:JAMF) show varied opinions, with a recent shift towards a more cautious outlook. Over the last quarter, ratings ranged from bullish to bearish, but the past 30 days have seen a unanimous move to 'Indifferent'. The 12-month price target average has decreased by 22.48% to $23.00, with a high estimate of $25.00 and a low of $20.00. Analysts from Barclays, Piper Sandler, RBC Capital, and Needham have adjusted their ratings and price targets, reflecting changes in market conditions and company performance. Jamf Holding, specializing in Apple Enterprise Management, has shown a revenue growth of 14.51% but struggles with a net margin of -22.63% and an ROA of -2.09%. Its debt-to-equity ratio is healthy at 0.52, and it has an ROE of -4.59%.

Portfolio Pulse from Benzinga Insights

January 12, 2024 | 2:00 pm

FANG

Mizuho analyst Nitin Kumar has maintained a Buy rating on Diamondback Energy (NASDAQ:FANG) but has reduced the price target from $178 to $177.

Portfolio Pulse from Benzinga Newsdesk

January 12, 2024 | 1:57 pm

ABT

UBER

URNM

VRTX

On CNBC's 'Halftime Report Final Trades,' analysts provided updates on Uber Technologies, Sprott Uranium Miners ETF, Abbott Laboratories, and Vertex Pharmaceuticals. Uber's stock hit an all-time high, with a raised price target from Goldman Sachs. Uranium is expected to have another strong year, supporting URNM. Abbott Laboratories received a higher price target from RBC Capital. Vertex Pharmaceuticals also reached an all-time high and announced the approval of a gene-edited therapy in Saudi Arabia. Stock movements included gains for Uber and Vertex, while URNM and Abbott Laboratories saw declines.

Portfolio Pulse from Avi Kapoor

January 12, 2024 | 1:51 pm

RPM

Mizuho analyst John Roberts has initiated coverage on RPM International Inc. (NYSE:RPM) with a Buy rating and set a price target of $128.

Portfolio Pulse from Benzinga Newsdesk

January 12, 2024 | 1:50 pm